Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy.
- Citation data:
American heart journal, ISSN: 1097-6744, Vol: 156, Issue: 2, Page: 367-72
- Publication Year:
- Repository URL:
- Medicine; Cardiomyopathies; Defibrillators; Implantable; Disease-Free Survival; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Ventricular Dysfunction; Left; Defibrillators, Implantable; Ventricular Dysfunction, Left; Analytical, Diagnostic and Therapeutic Techniques and Equipment; Cardiovascular Diseases
Women have been underrepresented in randomized trials of implantable cardioverter defibrillator (ICD) therapy, and limited data suggest that women may not benefit from prophylactic ICD implantation to the same extent as men. In the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial, a reduction in all-cause mortality was seen in men (P = .018) but not for women (P = .76).